Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cross-stage, cross-species malaria CD8<sup>+</sup> T cell antigens.

Nature·2026
Same author

A cell-death protein has an unexpected role in intestinal repair.

Nature·2026
Same author

Pyroptosis: Turning Up the Heat on Cancer.

Annual review of immunology·2026
Same author

Innate immunity in tumour immunoediting and immunosurveillance.

The EMBO journal·2025
Same author

ER-resident CCDC134 safeguards TLR4 maturation by maintaining gp96 stability.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol.

Nature communications·2025

Related Experiment Video

Updated: Apr 5, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K

Knocking down disease: a progress report on siRNA therapeutics.

Anders Wittrup1, Judy Lieberman2

  • 11] Program in Cellular and Molecular Medicine, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA. [2] Department of Clinical Sciences, Section for Oncology and Pathology, Lund University, 221 85 Lund, Sweden.

Nature Reviews. Genetics
|August 19, 2015
PubMed
Summary

Small interfering RNA (siRNA) therapeutics show promise for treating diseases by silencing gene expression. Recent clinical trials demonstrate effective liver gene knockdown with good safety, advancing siRNA drug development.

More Related Videos

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.7K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Related Experiment Videos

Last Updated: Apr 5, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.7K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Pharmacology

Background:

  • Gene silencing using small interfering RNAs (siRNAs) offers therapeutic potential by inhibiting disease-associated protein synthesis.
  • Effective delivery of siRNA molecules into target cells remains a significant challenge for therapeutic applications.
  • Recent advancements have enabled successful siRNA delivery for gene expression suppression in the liver.

Purpose of the Study:

  • To review the clinical trial outcomes of siRNA therapeutics targeting liver gene expression.
  • To assess the efficacy, durability, and safety profile of siRNA drugs in clinical settings.
  • To identify challenges and potential strategies for expanding siRNA therapeutics beyond the liver.

Main Methods:

  • Review of recent clinical trial data for siRNA therapeutics.
  • Analysis of gene knockdown efficiency and duration in liver tissues.
  • Evaluation of clinical outcomes and toxicity profiles.

Main Results:

  • Clinical trials show efficient and durable gene knockdown in the liver following siRNA administration.
  • siRNA therapeutics in liver applications exhibit promising clinical outcomes with minimal toxicity.
  • Successful delivery into the liver cytosol has been achieved, overcoming a major hurdle.

Conclusions:

  • siRNA therapeutics have demonstrated significant success in liver-targeted gene silencing.
  • The established efficacy and safety in the liver pave the way for broader therapeutic applications.
  • Overcoming delivery barriers is key to expanding siRNA therapy to non-hepatic tissues.